Retatrutide is best known for weight loss, but a new post hoc analysis of two phase 2 trials looked at what it did to the blood. Large triglyceride-rich lipoprotein particles fell by up to 84.4% in adults with type 2 diabetes, and ApoB dropped by roughly 21–24%. In the trial without diabetes, hsCRP fell 54.8% and IL-6 fell 29.6%, but those changes were not significant in the diabetes trial. The abstract reports no Lp(a) results and no per-dose breakdown. This is an unapproved prescription-class drug, not a supplement, and these are biomarkers, not proof of fewer heart attacks.
This page is available in